Treats acquired immunodeficiency syndrome (AIDS). ANDA 76222, held by Hikma. Ganciclovir Sodium.
As of Nov 16, 2026, ANDA 76222 (Ganciclovir Sodium), held by Hikma, was first approved by FDA on Jul 16, 2003, with 3 approved supplements and 0 published complete response letters.
Ganciclovir for Injection, USP is a deoxynucleoside analogue cytomegalovirus (CMV) DNA polymerase inhibitor indicated for the: treatment of CMV retinitis in immunocompromised adult patients, including patients with acquired immunodeficiency syndrome (AIDS). prevention of CMV disease in adult transplant recipients at risk for CMV disease. 1.1 Treatment of CMV Retinitis Ganciclovir for Injection, USP is indicated for the treatment of cytomegalovirus (CMV) retinitis in immunocompromised adult patients, including patients with acquired immunodeficiency syndrome (AIDS). 1.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jul 16, 2003 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Ganciclovir SodiumEQ 500MG BASE/VIAL · injectable;injection | Ganciclovir Sodium | Rx |
| Mar 27, 2025 | Supplement 7Labeling · Standard review | Approved | None posted |
| May 5, 2021 | Supplement 6Labeling · Standard review | Approved | None posted |
| Feb 26, 2009 | Supplement 2Labeling | Approved | None posted |
| Jul 16, 2003 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters